First Impressions... - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

First Impressions...


Special from Pharmaceutical Technology


It is clear from my visit that China is on the rise as a center for pharmaceutical R&D, but the trend is still in its early stages. Pharmaceutical companies are still getting their footing for operating in China, and the pharmaceutical services industry still has a lot of maturing to do.

One scene at the Impact China II conference captured the state of affairs for me. On one side of the conference hall sat a five-member team from a major pharmaceutical company that came to explore how its company should establish operations in China. On the other side of the hall sat a senior research scientist who was there at his own expense to determine whether he should accept an offer from a venture capital firm that was recruiting him to lead a CRO start-up.

He worked for the same Big Pharma company that sent the five-member team.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Special from Pharmaceutical Technology,
Click here